News | November 21, 2011

VEITH Symposium Chairman Strongly Contests AHA Guidelines for Use of Carotid Artery Stenting in Symptomatic Patients

November 21, 2011 - Frank J. Veith, M.D., founder and chairman of the VEITH symposium, the William J. von Liebig Chair in Vascular Surgery, Cleveland Clinic and New York University Medical Center, took a strong position against the current guidelines of the American Heart Association (AHA) that support the use of carotid artery stenting (CAS), as opposed to the more traditional open carotid endarterectomy (CEA), to treat symptomatic carotid stenosis (CS) in low to moderate risk patients. Veith explained to an audience of his peers that an important clinical trial for CAS, the CREST (Carotid Revascularization Endarterectomy vs. Stent Trial), had results that appeared to show that the stent procedure (CAS) and the open surgical approach (CEA) were equivalent. Veith argued that the study was in fact flawed in several ways and that the AHA guideline was misguided.

The CREST study was designed to compare CEA and CAS in only symptomatic patients, but poor recruitment led to the inclusion of some asymptomatic patients. Adding these patients to the pool diluted the intended power of the original study, as asymptomatic patients with carotid stenosis have a different pathology and natural disease history. The study’s primary endpoint included death, stroke and myocardial infarction, and the difference in this combination endpoint for the CAS and CEA groups was in fact not significantly different. But Veith pointed out that when the individual endpoints (like total, major and minor strokes) were individually examined there were large differences in the incidence of these events in the two groups. However, since the additional asymptomatic patients had been added to the study population, these important findings were not significantly different and the AHA concluded from the results that the two procedures had similar results and therefore CAS could now be viewed as an alternative.

There were other challenges with the design and conduct of the study, including that the skills of the CAS physicians in this study were superior to and not representative of those doing the procedure in the “real world.” In addition, the CAS patients received more intensive antiplatelet treatment that the CEA patients, leading to possibly a lower MI rate after CAS.

Veith’s main assertion was that, because CAS causes more strokes than CEA, CAS is currently inferior to CEA, and CAS should not be considered an alternative or equivalent to CAE in most symptomatic patients and therefore the AHA guidelines are “misguided.”

For more information: www.VEITHpress.org

Related Content

The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral Vascular's Covera Vascular Covered Stent for the treatment of a stenosis or blockage which has developed anywhere in the access circuit of patients on hemodialysis using an arteriovenous (AV) fistula.
Technology | Stents | April 03, 2019
April 3, 2019 — The U.S.

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market. 

Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S.
The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years
The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few year
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
Overlay Init